HC Wainwright & Co. Maintains Buy on Autolus Therapeutics, Raises Price Target to $10
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Emily Bodnar maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from $9 to $10.
HC Wainwright & Co. analyst Emily Bodnar maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from $9 to $10.